Long-term results of a phase 3 trial show that early rituximab monotherapy significantly delays the need for new treatment in ...

Two new RCTs of rituximab will soon begin in the United Kingdom: A biomarker-based trial with add-on belimumab and another in ...

Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low ...

Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three ...

Combination rituximab and IVIG therapy may be a viable treatment option for patients with refractory autoimmune diseases, though the quality of evidence is low.

The "Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.This ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

Future research into non-Hodgkin lymphoma treatments needs to explore long-term outcomes and a better understanding biologic ...

Q1 2025 Earnings Call Transcript May 14, 2025 ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.36, ...

Operator: Ladies and gentlemen, thank you for standing by, and welcome. At this time all participants are in listen-only mode ...